Does the anti-viral agent, remdesivir, improve outcomes in hospitalized patients with COVID-19? This multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy of remdesivir in hospitalized patients with COVID-19. The study included 1062 patients and demonstrated that a 10-day course of remdesivir significantly reduced the median time to recovery (from 15 days to 10 days) compared to placebo. While there was a trend toward reduced mortality in the remdesivir group (11.4% vs. 15.2%), this finding did not reach statistical significance. The trial established remdesivir as the first antiviral agent to show clinical benefit in COVID-19, particularly for patients requiring oxygen support but not yet on mechanical ventilation. The ACTT-1 trial reveals how remdesivir shortens recovery time for hospitalized COVID-19 patients, marking a milestone in antiviral therapy.